The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | RINGSIDE: data from the safety analysis of varegacestat in desmoid tumors
Piotr Rutkowski, MD, PhD, Curie National Research Institute, Warsaw, Poland, discusses a detailed safety analysis from the Phase III RINGSIDE (NCT04871282) trial of once-daily varegacestat, a gamma-secretase inhibitor, versus placebo in adults with progressing desmoid tumors. Adverse events, most commonly diarrhea, fatigue, rash, and nausea, were more frequent with varegacestat, alongside electrolyte abnormalities and ovarian toxicity in premenopausal women that resolved in some cases. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Read more...